Corcept Therapeutics Announces Positive Phase 2 BELLA Trial Results for Lifyorli Combination in Ovarian Cancer

Corcept Therapeutics reported positive Phase 2 BELLA trial results for Lifyorli combined with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer. The regimen achieved median progression-free survival of 7.2 months and an objective response rate of 59%; 88% of patients were alive at the six-month overall-survival timepoint. The results mark a clinical update for Corcept’s oncology development program; the article did not report financial results or a stock-price reaction.